[Skip to Content]
[Skip to Content Landing]
Research Letter
August 2016

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma

Author Affiliations
  • 1Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 3Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge
  • 4Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
  • 5Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. 2016;2(8):1094-1096. doi:10.1001/jamaoncol.2016.1056

Neoadjuvant cisplatin-based chemotherapy (NACC) is a standard of care for muscle-invasive urothelial bladder carcinoma (MIBC), and complete responses at cystectomy are associated with improved overall survival. Somatic mutations in ERCC2, a member of the nucleotide excision repair pathway, correlated with pathologic response in a clinical discovery cohort and conferred cisplatin sensitivity in preclinical systems.1 Herein, we investigate this association in an independent validation patient cohort.

First Page Preview View Large
First page PDF preview
First page PDF preview